BARDA, DOD backing of I-SPY COVID trial highlights continued need for new therapies

Vaccines are here, but the pandemic is far from over and BARDA and DOD are supporting the search for therapies to help the sickest COVID-19 patients by funding a mechanism that’s proving to be most efficient in identifying effective treatments.

HHS’s Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense are contributing $66.5 million to expand the I-SPY COVID platform trial through an agreement with its sponsor, Quantum Leap Healthcare Collaborative. ...